After the readout of ADVANCE in June, which showed a strong tendency towards effect across the two major measurements (ACR20 and DAS28-CRP), the company is testing resomelagon in two additional phase II studies: in dengue fever and pulmonary infections. The main driver in the medium term will be a potential deal for resomelagon. The company is funded potentially until Q3 2027 after a loan agreement of SEK100m. The SynAct share screens as "Fairly valued".
LÄS MER
